Form 8-K BIOMARIN PHARMACEUTICAL For: Aug 02
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/24/2026
- Wall Street ends lower on semiconductor selloff as AI spending concerns mount
- Alphabet added to Dow Jones Industrial Average, Verizon dropped
- Chip stocks plunge, but bargain-hunters limit scale of tech rout
- FedEx falls 4% as CY2026 profit forecast misses expectations despite Q4 beat
- Oil prices finish 1% lower as investors focus on Hormuz flows after peace talks
- Needham Starts NeoVolta (NEOV) at Buy
- Wall Street ends lower on semiconductor selloff as AI spending concerns mount
- NextEra to discuss paying about $76 per share for Dominion, Bloomberg News reports
- Campbell Soup (CPB) Declares $0.39 Quarterly Dividend; 7.7% Yield
- KKR launches Helix with over $10 billion to build AI infrastructure
BioMarin Pharmaceutical Inc. (BMRN) PT Raised to $126 at SunTrust Robinson Humphrey
August 3, 2018 2:32 PM EDTSunTrust Robinson Humphrey raised its price target on BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) to $126.00 (from $121.00) while maintaining a Buy rating.
Analyst Edward Nash commented, "BioMarin reported a strong 2nd quarter. All but Kuvan's net product sales beat Street consensus. Prior guidance... More
